Antibiotic – nemonoxacin

Published: 5-May-2010
Research & Development Pharmaceutical

Quinolone antibiotics prevent the bacteria’s DNA from unwinding, thus stopping them replicating

Quinolone antibiotics first reached the market in the 1960s, and work by preventing the bacteria’s DNA from unwinding, and thus stopping them replicating. The key target is the enzyme topoisomerase II, or DNA gyrase, and more recently introduced quinolone antibiotics such as ciprofloxacin and moxifloxacin have increased activity againt this enzyme.

However, there is a growing incidence of resistance against these key antibacterial agents; notably, the majority of strains of methicillin-resistant Streptococcus aureus are resistant to marketed quinolones. There is also significant resistance from several other bacteria, including Streptococcus pneumoniae and Pneumococcus influenzae. Therefore, there is a need for analogues of these otherwise potent antibiotics that retain activity against these resistant strains.

One such molecule that is under development is TaiGen Biotechnology’s nemonoxacin, which licensed the non-fluorinated quinolone drug from Procter & Gamble for development in a variety of Asian markets.1 It shows good activity against MRSA, multidrug resistant S. pneumoniae, vancomycin-resistant S. aureus and a wide range of other bacteria, both Gram positive and Gram negative.

Results of two Phase I trials have recently been published. In one 56 healthy subjects were enrolled in a double blind, ascending single dose study and randomised to one of seven dose cohorts.2 In each of these, two subjects were given placebo, and six single oral doses of between 25 and 1500mg nemonoxacin. It was well tolerated up to the maximum dose, and no serious adverse events were seen, with the most common being contact dermatitis, erythema and pruritis. Its peak time was 1 to 2 hours, and half-life between 9 and 16 hours.

In the second, 46 healthy volunteers were given oral doses of 75 to 1000mg once a day for 10 days.3 It was generally safe and well tolerated, with the most common side-effects being headache, contact dermatitis and rash. It was rapidly absorbed within 2 hours of dosing, and a steady state was achieved after 3 days in most subjects. The pharmacokinetics were affected by food, causing a decrease in plasma concentration, but free drug levels were good whether the subjects were fasting or fed.

A randomised, double blind Phase II trial has also been reported.4 Its efficacy was compared with that of levofloxacin in patients with community acquired pneumonia at once daily doses of 500 or 750mg for seven days. The most common pathogens involved were H. influenzae, S. pneumoniae and S. aureus. Clinical cure rates were 92% for the higher dose of nemonoxacin, 88% for the lower dose, and 94% for 500mg of levofloxacin. In addition, the company has recently announced by press release that it had shown promising clinical efficacy and good tolerability in a Phase II trial in patients with diabetic foot infections.

References

1. G.G. Zhanel et al. 48th Ann. Intersci. Conf. Antimicrob. Agents Chemother. Infect. Dis. Soc. Am. Ann. Meet. (Oct 25-28, Washington DC), 2008, Abst F1-2057; N. Laing et al. ibid. Abst. C1-1957
2. L. Lin et al. Antimicrob Agents Chemother. 2010, 54, 405
3. D.T. Chang et al. Antimicrob Agents Chemother. 2010, 54, 411
4. D.J. van Rensburg et al. 48th Ann. Intersci. Conf. Antimicrob. Agents Chemother. Infect. Dis. Soc. Am. Ann. Meet. (Oct 25-28, Washington DC), 2008, Abst. L-678
See more

You may also like

Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

Read more
The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results

Trending Articles

  1. Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling New X and S Series models offer high performance with reduced environmental impact
  2. Ardena strengthens executive leadership with key quality and IT appointments Appointments reflect focus on quality, compliance, and digital integration across global network
  3. Servier and University College London partner to advance research in rare genetic epileptic disorders Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
  4. AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
  5. Experts uncover how bacteria modify themselves to outsmart antibiotics Scientists from the University of Nottingham are part of an international collaboration which has taken a step closer to understanding why bacteria can become resistant to antibiotics

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development

Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend

Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Research & Development

Global myalgic encephalomyelitis study identifies 250+ core genes and shared biology with long COVID

PrecisionLife’s large-scale genomic analysis reveals major biological drivers of ME and its overlap with long COVID, identifying dozens of drug repurposing opportunities and paving the way for more targeted clinical trials
Research & Development

Servier and University College London partner to advance research in rare genetic epileptic disorders

Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
Subscribe now